Mastering the Art of Prior Authorization to Improve Patient Access to PCSK9 Inhibitors

Release date: June 19, 2019
Expiration date: June 19, 2020
Estimated Time to Complete Activity: 0.75 Hour(s)

 

FACULTY

James A. Underberg MS, MD, FACP, FNLA
Clinical Assistant Professor of Medicine
NYU School of Medicine
NYU Center for Prevention of Cardiovascular Disease
Director Bellevue Hospital Lipid Clinic
New York, New York

Kevin C. Maki, PhD
Adjunct Faculty in Biostatistics and Epidemiology
DePaul University
Chief Scientist
Midwest Biomedical Research/Center for Metabolic & Cardiovascular Health
Chicago, Illinois

PROGRAM OVERVIEW

This program is designed to summarize the latest clinical trial evidence regarding PCSK9i, as well as the latest clinical recommendations for the use of PCSK9i. It will include a discussion of common barriers to PCSK9i prescription approval and recommend potential solutions to overcome these obstacles and improve patient access to PCSK9i.

TARGET AUDIENCE

This educational activity is directed toward lipidologists, cardiologists, nurse practitioners, physician assistants, and other specialty healthcare providers (HCPs) interested in the treatment of hypercholesterolemia.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be better able to:

  • Summarize the findings from CV outcomes studies of PCSK9i
  • Identify specific patient populations that would benefit from LDL-C lowering utilizing PCSK9i therapies
  • Apply the guidance from the latest clinical recommendations for the use of PCSK9i
  • Implement strategies to overcome common obstacles and potential solutions to increase patient access to PCSK9i
DIRECTIONS TO THE LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of June 19, 2019 through June 19, 2020, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

MEDIA

Internet

ACCREDITATION STATEMENT

Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education designates this enduring material for a maximum of .75 AMA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or information@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

James Underberg, MD
Consulting Fees: Amarin, Amgen
Fees for non-CME Services: Amarin, Alexeron, Amgen, Regeneron, Sanofi
Contracted Research: Aegerion, Pfizer and Sanofi
Other (Steering Committee Member): Aegerion Lower Registry Trial

Kevin C. Maki, PhD
Consulting Fees: Abbott, Amegen, Corvidia Therapeutics, Matinas BioPharma, Pharmavite
Contracted Research: Abbott, Amgen
Ownership Interest: Amgen, Amarin

The Integrity CE planners/managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10

Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.

PROVIDER STATEMENT

This CME activity is provided by Integrity Continuing Education.

SUPPORTER ACKNOWLEDGMENT

This activity is supported by educational funding provided by Amgen.

Continue to Pretest